Pazopanib for treating rhabdomyosarcoma in adult patients with poor performance status: A case report [PDF]
Thoracic Cancer, 2022 Rhabdomyosarcoma (RMS) is a common soft tissue sarcoma usually observed in children. However, RMS rarely occurs in adults. The prognosis of adult RMS is poor and a standard chemotherapy regimen has not yet been established.
Yuuya Nishii +7 more
doaj +5 more sources
Survival prognostic factors in nonsmall cell lung cancer patients with simultaneous brain metastases and poor performance status at initial presentation [PDF]
HeliyonPurpose: Although the treatment of nonsmall cell lung cancer (NSCLC) has rapidly progressed recently, there is little evidence of treatment for patients with symptomatic brain metastases (BM) and poor performance status (PS).
Kyoko Sumiyoshi +6 more
doaj +4 more sources
Chemotherapy in geriatric patients with poor performance status small cell lung cancer: Series from a tertiary care center [PDF]
Aging Medicine, 2022 Deepak Sundriyal +3 more
doaj +3 more sources
Radiotherapy for glioblastoma patients with poor performance status. [PDF]
J Cancer Res Clin Oncol, 2022 Abstract Purpose There is limited information on treatment recommendations for glioblastoma patients with poor performance status. Here, we aim to evaluate the association of radiotherapy on survival in glioblastoma patients presenting with poor postoperative performance status in first-line setting.
Schröder C +6 more
europepmc +5 more sources
Feasibility of fast, four-dimensional computed tomography-based O-ring LINAC plans for lung stereotactic body radiotherapy in patients with poor performance status [PDF]
Frontiers in Oncology, 2023 PurposeWe aimed to retrospectively analyzed the feasibility of fast four-dimensional computed tomography (4DCT)-based O-ring LINAC treatment for patients with an average respiratory amplitude was< 0.5 cm and who cannot endure long treatment times due ...
Eun Jeong Heo +10 more
doaj +2 more sources
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study [PDF]
Frontiers in Oncology, 2022 ObjectivesWe investigated the efficacy and safety of pembrolizumab monotherapy as first-line treatment for poor Eastern Cooperative Oncology Group performance status (PS) and elderly patients with programmed cell death-ligand 1 (PD-L1)-positive advanced ...
Shinsuke Shiotsu +13 more
doaj +2 more sources
Dramatic response to alectinib in an ALK‐positive LCNEC patient with a poor performance status: A case report [PDF]
Respirology Case Reports, 2021 The echinoderm microtubule‐associated protein‐like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene, a driver mutation in lung carcinoma, is fairly common in lung adenocarcinoma but rare in large cell neuroendocrine carcinoma (LCNEC). Here we report
Kazuki Masuda +8 more
doaj +2 more sources
Significance of poor performance status after resection of colorectal liver metastases [PDF]
World Journal of Surgical Oncology, 2018 Background Performance status (PS) is known as one of the strongest prognostic factors for survival in metastatic colorectal cancer patients. The aim of the present study was to analyze factors associated with poor PS assessed after resection for ...
Peter Strandberg Holka +5 more
doaj +3 more sources
A Case of Advanced Gastric Cancer with Poor Performance Status Which Improved by Chemotherapy [PDF]
Case Reports in Oncology, 2010 Introduction: The prognosis of advanced gastric cancer patients, especially those with poor performance status (PS), is generally dismally poor. Patients with PS 3–4 are usually ineligible for participation in clinical studies and are managed with only ...
Kohei Shitara, Daisuke Takahari
doaj +3 more sources
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040) [PDF]
BMC Cancer, 2022 Background Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, can be used in patients ...
Tomoya Fukui +7 more
doaj +2 more sources